• Atheer

  Participated · Series B · Dec 2015

  Atheer is a Mountain View, CA–based provider of an augmented interactive reality computing platform. Its platform combines augmented reality with intelligent gesture, voice and head‑motion interactions along with real‑time rich‑media collaboration to enhance productivity and safety for deskless professionals at Fortune 1000 companies. Atheer’s glasses enable users to view workflow‑critical information, interact naturally without holding a device, and collaborate with remote peers. The company offers an Android‑based augmented interactive reality OS and suite that developers and enterprises use to build productivity applications and workflows. Customers and partners include Dassault Systemes, Flex, KPIT, Masimo, Optech4D, TeamViewer, Zurich Insurance Company, Lumus and NVIDIA. Atheer closed a $14M Series B and will use the funds to accelerate go‑to‑market activities and global customer deployment. Atheer develops AiR, an augmented reality smart-glass platform that combines gesture control with AR and is Android-based for third-party developers. The company targets healthcare, logistics and the energy industry, positioning its glasses for hands-free use in operating rooms and at the patient bedside. Atheer highlights a design advantage over bulkier headsets by making its product look more like conventional glasses. Leadership includes founder Soulaiman Itani and CEO Alberto Torres, who say the company is prioritizing industrial and clinical customers ahead of consumers. Atheer is four years old and described as Silicon Valley–based. Financially, the company filed with the SEC showing an $8.8 million raise via a Form D filing. Atheer Labs is developing Atheer One, a pair of 3D augmented-reality glasses that connect to smartphones. The glasses display 3D apps and games appearing to float in front of the user's face and allow interaction by pointing a finger in the air. The company intends the device for both playful, game-style environments and professional fields such as medicine and logistics. A developer version is due out in the coming months and the company plans a consumer launch in Q4 2014. On the financing side, Atheer has an active $6.1M funding round (filed via Form D) and has raised $1.5M so far; it also ran an IndieGoGo campaign that has raised over $110,000 from more than 250 backers. Previous investors include Farzad Naimi of Rona Holdings and Bobby Yazdani of Saba Software.

• IntegenX

  Participated · Series C · Dec 2011

  IntegenX, based in Pleasanton, California, develops Rapid human DNA identification technology that integrates advanced fluidics, optics and biochemistry. Led by Chief Operating Officer David V. Smith, the company produces products for DNA-based human identity testing. Its technology is targeted at forensics and law enforcement applications. The company announced a financing to support operations and working capital. The article reports a $10M venture loan as the company’s latest financing activity. No revenue or user metrics were disclosed in the article. IntegenX develops rapid human DNA identification technology and DNA sequencing library-preparation systems, including the RapidHIT 200 biometric sample-to-profile system. The RapidHIT 200 is designed to enable law enforcement, government agencies, and forensic laboratories to provide real-time human DNA analysis. The company also offers the Apollo 324 automated NGS library-prep system and GenTegra and GenPlate products for dry-state stabilization and room-temperature storage of DNA, RNA, whole blood, and biological fluids. Led by CEO Stevan Jovanovich, Ph.D., IntegenX plans to use new funding to accelerate development of its product pipeline and commercialize the RapidHIT 200 in domestic and international markets. Financially, the company secured $40M in a Series C financing announced in December 2011. IntegenX raised $15.6M in its second financing round and recently acquired GenVault Corporation. The company designs, manufactures and markets automated DNA- and RNA-based sample-preparation systems. The acquisition adds GenVault’s GenTegra™ products to IntegenX’s portfolio, enabling transport and storage of biosamples without refrigeration and preventing degradation. The capital will fund commercialization of the Apollo 324 System for next-generation sequencing library preparation and development of the Apollo 200 RapidHIT™ System for DNA-based human identification. It will also support worldwide marketing of GenTegra™ products to increase the quality and value of data produced by IntegenX’s integrated systems. IntegenX is led by President and CEO Stevan Jovanovich, Ph.D. Microchip Biotechnologies develops integrated systems for microsample preparation and analysis. Its core product is the Apollo 100 System, a sample preparation system for Sanger DNA cycle sequencing. The company plans to commercialize the Apollo 100 and to extend the Apollo platform into the rapidly growing Next-Generation Sequencing market. It is also targeting emerging markets in DNA-based human identification and forensics. To support these efforts, Microchip recently completed a significant financing round. The company is based in Pleasanton, California.

No current team members are available.